Exosomes · Lesson 8 of 18 · 3 min

What is still unknown about exosomes?

Exosome science has clear gaps: mixed vesicle populations, uncertain fate in the body, poorly defined dose-response and weak standardization. Each one matters for clinical claims.

A gloved hand pipetting into small vials on a lab bench

Key takeaways.

  • Exosome preparations are mixtures of subpopulations that current methods cannot cleanly separate.
  • Which subpopulation causes an observed effect is often unclear.
  • Where exosomes go in the body and how they are cleared remains uncertain.
  • Dose-response relationships are poorly defined for most exosome applications.
  • Laboratories still use different methods and terms, which makes studies hard to compare.
  • Exosome therapies are not FDA-approved for therapeutic use.

Preparations are mixtures

Cells produce several exosome subpopulations that differ in size, density, markers and cargo. Current methods cannot cleanly separate them.

Any exosome preparation is therefore a mixture. The source notes that subpopulations may have distinct or even opposing functions. This makes it hard to say which vesicles cause an observed effect.

Fate in the body is uncertain

It is still unclear where administered exosomes go, how long they persist and how they are cleared. It is also unclear what fraction reaches a target tissue and what fraction is filtered by the liver or spleen.

Tracking is technically difficult. Labeling may change how exosomes distribute, and the vesicles are too small for most imaging methods.

Dose-response is poorly defined

Most studies test one or a few doses. Few map how effects change with the amount given.

Basic questions remain open. These include whether there is a threshold dose, whether effects plateau and whether excessive doses cause toxicity. The source describes this work as essential for clinical development and done for relatively few applications.

What this means for practice

Standardization is described as the field's most persistent challenge. Laboratories use different isolation methods, characterization approaches and terms, even with the MISEV2018 guidelines in place.

These gaps explain why evidence is limited and why claims deserve scrutiny. Exosome therapies are not FDA-approved for therapeutic use. Clinicians should weigh any proposed use against what is still unknown.

Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.

Exosomes: 0 of 18 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • How to weigh evidence gaps in clinical decisions
  • What to tell patients about what is known and unknown
  • Evaluating product and study claims
  • Regulatory position and risk management

Common questions.

Is there an established dose for exosomes?
No. The course material states that dose-response relationships remain poorly defined, with most studies testing only one or a few doses.
Where do exosomes go after administration?
This remains uncertain. Tracking exosomes in living subjects is technically difficult, so biodistribution data are limited.
Why is exosome research hard to compare across studies?
Laboratories use different isolation methods, characterization approaches and terminology, and no certified reference materials are available.

Sources

  • Kalluri, R., & LeBleu, V. S. (2020). The biology, function, and biomedical applications of exosomes. Science, 367(6478), eaau6977.
  • Théry, C., et al. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018). Journal of Extracellular Vesicles, 7(1), 1535750.
  • Witwer, K. W., & Théry, C. (2019). Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature. Journal of Extracellular Vesicles, 8(1), 1648167.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.